Stereotaxis to Report Second Quarter 2025 Financial Results on August 7, 2025
Stereotaxis (NYSE: STXS), a pioneer in surgical robotics for minimally invasive endovascular intervention, will release its Q2 2025 financial results on August 7, 2025 after market close. The company will host a conference call and webcast at 4:30 p.m. ET to discuss results and corporate developments.
Stereotaxis' technology has been utilized in treating over 150,000 patients globally across the United States, Europe, Asia, and other regions. The company specializes in developing robotic systems, instruments, and information solutions for interventional laboratories, focusing on enhancing physician care delivery with robotic precision and safety.
Stereotaxis (NYSE: STXS), pioniere nella robotica chirurgica per interventi endovascolari minimamente invasivi, pubblicherà i suoi risultati finanziari del secondo trimestre 2025 il 7 agosto 2025 dopo la chiusura del mercato. L'azienda terrà una conference call e una webcast alle 16:30 ET per discutere i risultati e gli sviluppi aziendali.
La tecnologia di Stereotaxis è stata utilizzata per trattare oltre 150.000 pazienti a livello globale, inclusi Stati Uniti, Europa, Asia e altre regioni. L'azienda è specializzata nello sviluppo di sistemi robotici, strumenti e soluzioni informative per laboratori interventistici, con l'obiettivo di migliorare l'assistenza medica fornita dai medici grazie alla precisione e sicurezza robotica.
Stereotaxis (NYSE: STXS), pionera en robótica quirúrgica para intervenciones endovasculares mínimamente invasivas, publicará sus resultados financieros del segundo trimestre de 2025 el 7 de agosto de 2025 después del cierre del mercado. La compañía realizará una conferencia telefónica y una transmisión en vivo a las 4:30 p.m. ET para analizar los resultados y los desarrollos corporativos.
La tecnología de Stereotaxis se ha utilizado en el tratamiento de más de 150,000 pacientes en todo el mundo, incluyendo Estados Unidos, Europa, Asia y otras regiones. La empresa se especializa en desarrollar sistemas robóticos, instrumentos y soluciones informáticas para laboratorios intervencionistas, enfocándose en mejorar la atención médica con precisión y seguridad robótica.
Stereotaxis (NYSE: STXS)는 최소 침습성 혈관 내 시술을 위한 외과용 로봇 분야의 선구자로서, 2025년 8월 7일 시장 마감 후 2025년 2분기 재무 실적을 발표할 예정입니다. 회사는 동부시간 오후 4시 30분에 실적 및 기업 동향을 논의하는 컨퍼런스 콜과 웹캐스트를 진행합니다.
Stereotaxis의 기술은 미국, 유럽, 아시아 등 전 세계에서 15만 명 이상의 환자 치료에 활용되었습니다. 이 회사는 중재실용 로봇 시스템, 기기 및 정보 솔루션 개발에 주력하며, 로봇의 정밀성과 안전성을 통해 의사의 치료 제공을 향상시키는 데 중점을 두고 있습니다.
Stereotaxis (NYSE : STXS), pionnier dans la robotique chirurgicale pour les interventions endovasculaires mini-invasives, publiera ses résultats financiers du deuxième trimestre 2025 le 7 août 2025 après la clôture du marché. La société organisera une conférence téléphonique et une diffusion en direct à 16h30 ET pour discuter des résultats et des évolutions de l'entreprise.
La technologie de Stereotaxis a été utilisée pour traiter plus de 150 000 patients dans le monde, notamment aux États-Unis, en Europe, en Asie et dans d'autres régions. L'entreprise se spécialise dans le développement de systèmes robotiques, d'instruments et de solutions d'information pour les laboratoires interventionnels, en mettant l'accent sur l'amélioration des soins prodigués par les médecins grâce à la précision et à la sécurité robotisées.
Stereotaxis (NYSE: STXS), ein Vorreiter im Bereich der chirurgischen Robotik für minimalinvasive endovaskuläre Eingriffe, wird seine Finanzergebnisse für das zweite Quartal 2025 am 7. August 2025 nach Börsenschluss veröffentlichen. Das Unternehmen wird um 16:30 Uhr ET eine Telefonkonferenz und einen Webcast abhalten, um die Ergebnisse und Unternehmensentwicklungen zu besprechen.
Die Technologie von Stereotaxis wurde weltweit bei der Behandlung von über 150.000 Patienten in den USA, Europa, Asien und weiteren Regionen eingesetzt. Das Unternehmen spezialisiert sich auf die Entwicklung von robotergestützten Systemen, Instrumenten und Informationslösungen für interventionelle Labore, mit dem Fokus, die ärztliche Versorgung durch robotische Präzision und Sicherheit zu verbessern.
- None.
- None.
ST. LOUIS, July 23, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2025 second quarter on Thursday, August 7, 2025 at the close of the U.S. financial markets. The Company will host a conference call and webcast at 4:30 p.m. ET that day to discuss the Company’s results and corporate developments.
| What: | Stereotaxis second quarter 2025 financial results conference call |
| When: | Thursday, August 7, 2025, at 4:30 p.m. ET (1:30 p.m. PT) |
| Dial In Number: | To access the live call, dial 888-596-4144 (US and Canada) or 1-646-968-2525 (International) and give the participant pass code 1064613. |
| Webcast: | To access the live and replay webcast, please visit the investor relations section of Stereotaxis’ website at http://ir.stereotaxis.com/. |
| Call Replay: | A phone replay of the call will be available for one month beginning approximately four hours following the end of the call. To request access for a replay of the conference call, please click here. |
About Stereotaxis
Stereotaxis (NYSE: STXS) is a pioneer and global leader in innovative surgical robotics for minimally invasive endovascular intervention. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, expand access to minimally invasive therapy, and enhance the productivity, connectivity, and intelligence in the operating room. Stereotaxis technology has been used to treat over 150,000 patients across the United States, Europe, Asia, and elsewhere. For more information, please visit www.stereotaxis.com.
Investor Contacts:
David L. Fischel
Chairman and Chief Executive Officer
Kimberly Peery
Chief Financial Officer
314-678-6100
Investors@Stereotaxis.com
FAQ
When will Stereotaxis (NYSE: STXS) report Q2 2025 earnings?
How can investors access Stereotaxis Q2 2025 earnings call?
How many patients have been treated with Stereotaxis technology?
What is Stereotaxis (STXS) main business focus?
